Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...

This article GlucoTrack And 2 Other Stocks Under $1 Insiders Are Buying originally appeared on Benzinga.com.

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring ...

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...

Glucotrack (NASDAQ:GCTK) on Tuesday reported the successful completion of its first in human clinical study, sending shares up ~60% in the morning trade. This study represents first real-time ...

Glucotrack (GCTK) announced the pricing of a “best efforts” public offering of approximately 2.6M shares of common stock. The offering price of ...

Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...

As you can see from the chart above the percentage of shares that are sold short for GlucoTrack has grown since its last report. This does not mean that the stock is going to fall in the near-term ...